Developer docs
API playgroundTry for free, no card

Search company profiles

InhaTarget Therapeutics

Full company profile

uuid000digo

Namestring
InhaTarget Therapeutics
Legal namestring
InhaTarget Therapeutics SRL
Websiteurl
inhatarget.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

InhaTarget Therapeutics is a Belgian clinical-stage biopharmaceutical company (InhaTarget Therapeutics SRL) spun out of the Université Libre de Bruxelles (ULB) in August 2019, headquartered in Gosselies with a research office at ULB's Campus de la Plaine in Brussels. The company develops innovative inhalation formulations — both dry powder for inhalation (DPI) and nanomedicine-based delivery systems — to treat severe respiratory diseases, with an initial focus on lung cancer. Its lead product, CIS-DPI, is a cisplatin-based dry powder formulation designed to be administered five times weekly at home via inhaler, in combination with standard-of-care immunotherapy (pembrolizumab with or without IV chemotherapy) for first-line Stage IV non-small cell lung cancer (NSCLC) patients.

The company's technology rests on two proprietary platforms derived from 15+ years of research at ULB's Unit of Pharmaceutics and Biopharmaceutics: (1) a dry powder formulation platform based on particle engineering that enables high lung deposition and tailored drug release for inhaled chemotherapy, and (2) a nanomedicine-based delivery platform that encapsulates STING (Stimulator of Interferon Gene) pathway agonists for targeted pulmonary immunotherapy. CIS-DPI entered a Phase I/IIa first-in-human trial in February 2023 under FAMHP authorization, running across five Belgian hospital sites (Institut Jules Bordet, AZ Delta, CHU Ambroise Paré, Grand Hôpital de Charleroi, CHU Liège). Two additional inhaled chemotherapy compounds and the STING pathway immunotherapy remain at preclinical stage.

Commercially, InhaTarget is pre-revenue with no approved products and no disclosed pricing. Its intended monetization path is one-time licensing or co-development partnerships with larger pharmaceutical companies for commercialization of approved inhaled products, supplemented historically by €7.3M in non-dilutive Wallonia public funding layered onto €6.9M in Series A equity raised across two rounds (Series A1 €3.6M in December 2019, Series A2 €3.3M in June 2022). The company employs 1–10 staff and is led by co-founders Frédéric De Coninck (CEO), Rémi Rosière (CSO), and Pr. Karim Amighi (Scientific Advisor, inventor on 15 patents).

Short descriptiontext

InhaTarget Therapeutics is a Belgian clinical-stage biotech spun out of ULB in 2019 that develops inhaled dry powder and nanomedicine formulations for severe respiratory diseases, with a lead cisplatin-based DPI product (CIS-DPI) in Phase I/IIa trials for Stage IV NSCLC.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersIxelles, Belgium
HQ citystring
Ixelles
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inhaled oncology therapeutics, dry powder inhalation, lung cancer chemotherapy, pulmonary drug delivery, nanomedicine immunotherapy
Industry2 codes
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Inhaled Oncology Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Inhaled Chemotherapy Products
TypeOne Time License
Description

InhaTarget is developing a pipeline of inhaled chemotherapy products (CIS-DPI as lead product, plus two preclinical-stage inhaled chemo compounds) for the treatment of lung cancer. Revenue would be generated through product sales following regulatory approval, likely commercialized via pharma partnerships or licensing deals given the oncology hospital/clinic administration model.

inhatarget.com
2Inhaled Immunotherapy (STING Pathway Nanomedicine)
TypeLicensing Royalties
Description

A breakthrough first-in-class inhaled immunotherapy targeting the STING pathway for lung cancer and potentially other pulmonary diseases. This product is currently in preclinical development. Revenue model would involve licensing or co-development partnerships with larger pharmaceutical companies upon demonstration of clinical efficacy.

inhatarget.com
3Non-dilutive Public Funding
TypeManaged Services
Description

The company has received multiple rounds of non-dilutive public funding: €2.8M completed with Series A1 (December 2019) and €4.5M completed with Series A2 (June 2022), from regional public funding bodies such as Wallonia, to support R&D and clinical development activities.

inhatarget.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

InhaTarget Therapeutics develops innovative inhalation formulations (dry powder for inhalation and nanomedicine-based delivery) to improve treatment of severe respiratory diseases, with a primary focus on lung cancer. The lead asset CIS-DPI is a cisplatin-based dry powder administered 5 times weekly at home in combination with standard-of-care immunotherapy for first-line Stage IV NSCLC patients, currently in Phase I/IIa clinical trials across 5 Belgian hospital sites. The pipeline additionally includes two preclinical inhaled chemotherapy compounds and a first-in-class inhaled STING-pathway immunotherapy nanomedicine.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CIS-DPI administered 5 times weekly at home (vs. every 3 weeks for conventional IV cisplatin), enabling significantly higher treatment frequency through bypass of systemic toxicities
+2 more records
Product overview1 text field

InhaTarget Therapeutics develops a portfolio of innovative inhalation formulations for severe respiratory diseases, with initial focus on lung cancer. The core portfolio consists of CIS-DPI, a lead cisplatin-based dry powder formulation for inhalation currently in Phase I/IIa clinical trials, supported by two additional inhaled chemotherapy products at preclinical stage. The company also develops a breakthrough STING pathway immunotherapy based on inhaled nanomedicine, currently in preclinical development. All products leverage pulmonary delivery to overcome systemic limitations and improve patient outcomes.

Product and service3 records
1CIS-DPI
CategoryInhaled oncology therapeutics — lead product
Description

Cisplatin-based dry powder formulation for inhalation administered 5 times weekly at the patient's home in combination with standard-of-care immunotherapy (pembrolizumab with or without IV chemotherapy) for first-line treatment of Stage IV Non-Small Cell Lung Cancer patients. Currently in Phase I/IIa clinical trial (CIS-DPI-01) in Belgium.

2STING Pathway Inhaled Immunotherapy
CategoryInhaled immunotherapy — preclinical pipeline
Description

First-in-class inhaled nanomedicine targeting the STING (stimulator of interferon gene) pathway for anti-tumour immune response; functionalized nanocarrier encapsulates STING agonists and targets immunosuppressive tumor-associated macrophages and dendritic cells to convert them to a pro-inflammatory phenotype and induce systemic anti-tumour immunity, with potential applications beyond lung cancer including respiratory viral infections.

3Other Inhaled Chemotherapy Products (Preclinical Pipeline)
CategoryInhaled chemotherapy — preclinical pipeline
Description

Two additional inhaled chemotherapy compounds at preclinical development stage targeting different patient populations (squamous NSCLC, non-squamous NSCLC, adenocarcinoma) through specific formulations for the inhalation route, leveraging InhaTarget's particle-engineering dry-powder platform.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Institut Jules Bordet
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Institut Jules Bordet (Brussels, Belgium) is one of the 5 hospital sites conducting the CIS-DPI-01 Phase I/IIa clinical trial. Principal investigator: Pr. Thierry Berghmans. As a leading cancer center in Belgium, Institut Jules Bordet provides clinical trial infrastructure and oncology expertise for the investigation of CIS-DPI in stage IV NSCLC patients.

inhatarget.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

AZ Delta (Roeselare, Belgium) is a clinical trial site for the CIS-DPI-01 Phase I/IIa trial. Principal investigator: Pr. Ingel Demedts. AZ Delta provides clinical operations infrastructure for investigating CIS-DPI in stage IV NSCLC patients.

3CHU Ambroise Paré
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

CHU Ambroise Paré (Mons, Belgium) is a clinical trial site for the CIS-DPI-01 Phase I/IIa trial. Principal investigator: Dr. Stephane Holbrechts. The hospital provides oncology clinical trial capabilities for the investigation of inhaled cisplatin in lung cancer patients.

inhatarget.com
4Grand Hôpital de Charleroi (GHdC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Grand Hôpital de Charleroi (Charleroi, Belgium) is a clinical trial site for the CIS-DPI-01 Phase I/IIa trial. Principal investigator: Dr. Benoît Colinet. Located in the same region as the company's headquarters, GHdC provides clinical trial infrastructure for the CIS-DPI investigation.

inhatarget.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

CHU Liège (Liège, Belgium) is a clinical trial site for the CIS-DPI-01 Phase I/IIa trial. Principal investigator: Dr. Anne Sibille. CHU Liège provides oncology clinical trial capabilities for the investigation of inhaled cisplatin-based dry powder in combination with standard-of-care immunotherapy in stage IV NSCLC.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-12-01
Description

SMB Technology is a Belgian-based pharmaceutical company specialized in innovative drug formulations, particularly respiratory products based on Dry Powder for Inhalation (DPI) technologies. SMB Technology is represented on InhaTarget's Board of Directors by Mrs. Caroline Baudier (Managing Director), bringing solid expertise in inhalation project development. SMB is part of the SMB group dedicated to R&D and production of innovative pharmaceutical products using advanced drug delivery solutions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-08-01
Description

InhaTarget Therapeutics is a spin-off company from the University of Brussels (ULB), specifically from the Unit of Pharmaceutics and Biopharmaceutics led by Pr. Karim Amighi and Pr. Nathalie Wauthoz. The technology platform underlying the company's activities is the result of more than 15 years of research at ULB. The company's scientific advisors and co-founders are affiliated with ULB, and the Brussels office is located at ULB Campus de la Plaine.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Vectura is a UK-based specialty inhaled drug delivery company developing DPI and nebulized formulations for respiratory diseases, comparable to InhaTarget's inhaled chemo and pulmonary delivery platform. Now owned by Philip Morris, it represents the type of strategic acquirer/licensor that InhaTarget's assets could attract.

TypeDirect peer
Description

Pulmatrix is a US clinical-stage biopharmaceutical company developing inhaled therapies for respiratory diseases using proprietary dry powder and iSPERSE technology. Directly comparable as a small-cap inhaled drug delivery peer with similar business model and platform-based pipeline approach.

TypeDirect peer
Description

Savara is a clinical-stage specialty pharma developing inhaled therapies for rare respiratory diseases (e.g., molgramostim nebulization). Comparable as a small-cap inhaled therapeutic company pursuing hospital-administered and home-administered inhaled biologics/small molecules for serious pulmonary conditions.

4TFF Pharmaceuticals
TypeDirect peer
Description

TFF Pharmaceuticals applies thin-film freezing technology to enable dry powder inhalation of molecules that are otherwise difficult to deliver to the lungs. Directly comparable as a platform-based inhaled drug delivery company pursuing multiple indications including oncology and infectious disease.

5Aradigm Corporation
TypeDirect peer
Description

Aradigm developed inhaled liposomal ciprofloxacin (Aeroquin) and other inhaled therapeutics for severe respiratory infections. Comparable as a clinical-stage inhaled specialty pharma focused on serious pulmonary diseases, though it has since wound down commercial operations.

6Civitas Therapeutics
TypeDirect peer
Description

Civitas Therapeutics developed inhaled levodopa (ARCUS) for Parkinson's disease using a dry powder pulmonary delivery platform. Directly comparable as a small clinical-stage inhaled specialty pharma acquired by Acorda Therapeutics — representative of typical exit pathway for this peer group.

TypeEmerging player
Description

Aprea is a clinical-stage oncology biotech developing small molecules that reactivate tumor suppressor p53. Comparable as a similarly-sized clinical-stage oncology biotech, though with a different delivery modality (oral/systemic vs. inhaled).

8Synspira Therapeutics
TypeEmerging player
Description

Synspira develops inhaled glycopolymer-based therapies for cystic fibrosis and other chronic respiratory diseases. Comparable as a niche inhaled therapeutic company focused on serious pulmonary indications with similar formulation technology approach.

9SMB Technology
TypeOthers
Description

Belgian pharmaceutical company specialized in DPI formulation and inhalation product development; InhaTarget's Board partner and effective CDMO. Comparable as a domain peer and key ecosystem enabler for inhaled drug development in the same geography.

TypeEmerging player
Description

Novocure develops Tumor Treating Fields, an alternative physical modality for solid tumors including NSCLC. Comparable as a later-stage commercial-stage oncology company that built a niche around non-chemo/non-systemic treatment of lung cancer — relevant for understanding the commercial opportunity for non-systemic lung cancer therapies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InhaTarget Therapeutics

Inhaled Oncology Therapeuticsinhatarget.com

InhaTarget Therapeutics is a Belgian clinical-stage biotech spun out of ULB in 2019 that develops inhaled dry powder and nanomedicine formulations for severe respiratory diseases, with a lead cisplatin-based DPI product (CIS-DPI) in Phase I/IIa trials for Stage IV NSCLC.

What InhaTarget Therapeutics does

InhaTarget Therapeutics is a Belgian clinical-stage biopharmaceutical company (InhaTarget Therapeutics SRL) spun out of the Université Libre de Bruxelles (ULB) in August 2019, headquartered in Gosselies with a research office at ULB's Campus de la Plaine in Brussels. The company develops innovative inhalation formulations — both dry powder for inhalation (DPI) and nanomedicine-based delivery systems — to treat severe respiratory diseases, with an initial focus on lung cancer. Its lead product, CIS-DPI, is a cisplatin-based dry powder formulation designed to be administered five times weekly at home via inhaler, in combination with standard-of-care immunotherapy (pembrolizumab with or without IV chemotherapy) for first-line Stage IV non-small cell lung cancer (NSCLC) patients.

The company's technology rests on two proprietary platforms derived from 15+ years of research at ULB's Unit of Pharmaceutics and Biopharmaceutics: (1) a dry powder formulation platform based on particle engineering that enables high lung deposition and tailored drug release for inhaled chemotherapy, and (2) a nanomedicine-based delivery platform that encapsulates STING (Stimulator of Interferon Gene) pathway agonists for targeted pulmonary immunotherapy. CIS-DPI entered a Phase I/IIa first-in-human trial in February 2023 under FAMHP authorization, running across five Belgian hospital sites (Institut Jules Bordet, AZ Delta, CHU Ambroise Paré, Grand Hôpital de Charleroi, CHU Liège). Two additional inhaled chemotherapy compounds and the STING pathway immunotherapy remain at preclinical stage.

Commercially, InhaTarget is pre-revenue with no approved products and no disclosed pricing. Its intended monetization path is one-time licensing or co-development partnerships with larger pharmaceutical companies for commercialization of approved inhaled products, supplemented historically by €7.3M in non-dilutive Wallonia public funding layered onto €6.9M in Series A equity raised across two rounds (Series A1 €3.6M in December 2019, Series A2 €3.3M in June 2022). The company employs 1–10 staff and is led by co-founders Frédéric De Coninck (CEO), Rémi Rosière (CSO), and Pr. Karim Amighi (Scientific Advisor, inventor on 15 patents).

InhaTarget Therapeutics firmographics

Firmographics
Name
InhaTarget Therapeutics
Legal name
InhaTarget Therapeutics SRL
Website
https://inhatarget.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
InhaTarget Therapeutics is a Belgian clinical-stage biotech spun out of ULB in 2019 that develops inhaled dry powder and nanomedicine formulations for severe respiratory diseases, with a lead cisplatin-based DPI product (CIS-DPI) in Phase I/IIa trials for Stage IV NSCLC.
Ownership category
akta.pro rank

InhaTarget Therapeutics industry classification

Industry
Product category
Inhaled Oncology Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Inhaled oncology therapeutics
  • Dry powder inhalation
  • Lung cancer chemotherapy
  • Pulmonary drug delivery
  • Nanomedicine immunotherapy

Where InhaTarget Therapeutics is headquartered

Location

Headquarters

HQ city
Ixelles
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

InhaTarget Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

  1. Inhaled Chemotherapy Products: InhaTarget is developing a pipeline of inhaled chemotherapy products (CIS-DPI as lead product, plus two preclinical-stage inhaled chemo compounds) for the treatment of lung cancer. Revenue would be generated through product sales following regulatory approval, likely commercialized via pharma partnerships or licensing deals given the oncology hospital/clinic administration model.
  2. Inhaled Immunotherapy (STING Pathway Nanomedicine): A breakthrough first-in-class inhaled immunotherapy targeting the STING pathway for lung cancer and potentially other pulmonary diseases. This product is currently in preclinical development. Revenue model would involve licensing or co-development partnerships with larger pharmaceutical companies upon demonstration of clinical efficacy.
  3. Non-dilutive Public Funding: The company has received multiple rounds of non-dilutive public funding: €2.8M completed with Series A1 (December 2019) and €4.5M completed with Series A2 (June 2022), from regional public funding bodies such as Wallonia, to support R&D and clinical development activities.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

InhaTarget Therapeutics product offering

Product offering

Core offering

InhaTarget Therapeutics develops innovative inhalation formulations (dry powder for inhalation and nanomedicine-based delivery) to improve treatment of severe respiratory diseases, with a primary focus on lung cancer. The lead asset CIS-DPI is a cisplatin-based dry powder administered 5 times weekly at home in combination with standard-of-care immunotherapy for first-line Stage IV NSCLC patients, currently in Phase I/IIa clinical trials across 5 Belgian hospital sites. The pipeline additionally includes two preclinical inhaled chemotherapy compounds and a first-in-class inhaled STING-pathway immunotherapy nanomedicine.

Product overview

InhaTarget Therapeutics develops a portfolio of innovative inhalation formulations for severe respiratory diseases, with initial focus on lung cancer. The core portfolio consists of CIS-DPI, a lead cisplatin-based dry powder formulation for inhalation currently in Phase I/IIa clinical trials, supported by two additional inhaled chemotherapy products at preclinical stage. The company also develops a breakthrough STING pathway immunotherapy based on inhaled nanomedicine, currently in preclinical development. All products leverage pulmonary delivery to overcome systemic limitations and improve patient outcomes.

Differentiator

Problem solved

Functional benefit

Products and services

  • CIS-DPI Cisplatin-based dry powder formulation for inhalation administered 5 times weekly at the patient's home in combination with standard-of-care immunotherapy (pembrolizumab with or without IV chemotherapy) for first-line treatment of Stage IV Non-Small Cell Lung Cancer patients. Currently in Phase I/IIa clinical trial (CIS-DPI-01) in Belgium.
  • STING Pathway Inhaled Immunotherapy First-in-class inhaled nanomedicine targeting the STING (stimulator of interferon gene) pathway for anti-tumour immune response; functionalized nanocarrier encapsulates STING agonists and targets immunosuppressive tumor-associated macrophages and dendritic cells to convert them to a pro-inflammatory phenotype and induce systemic anti-tumour immunity, with potential applications beyond lung cancer including respiratory viral infections.
  • Other Inhaled Chemotherapy Products (Preclinical Pipeline) Two additional inhaled chemotherapy compounds at preclinical development stage targeting different patient populations (squamous NSCLC, non-squamous NSCLC, adenocarcinoma) through specific formulations for the inhalation route, leveraging InhaTarget's particle-engineering dry-powder platform.

Quantifiable outcome

  • CIS-DPI administered 5 times weekly at home (vs. every 3 weeks for conventional IV cisplatin), enabling significantly higher treatment frequency through bypass of systemic toxicities
  • +2 more outcomes

Companies that use InhaTarget Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

InhaTarget Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

InhaTarget Therapeutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • Institut Jules BordetcoreStrategic or Co-development Partner · 1 February 2023Institut Jules Bordet (Brussels, Belgium) is one of the 5 hospital sites conducting the CIS-DPI-01 Phase I/IIa clinical trial. Principal investigator: Pr. Thierry Berghmans. As a leading cancer center in Belgium, Institut Jules Bordet provides clinical trial infrastructure and oncology expertise for the investigation of CIS-DPI in stage IV NSCLC patients.
  • AZ DeltacoreStrategic or Co-development Partner · 1 February 2023AZ Delta (Roeselare, Belgium) is a clinical trial site for the CIS-DPI-01 Phase I/IIa trial. Principal investigator: Pr. Ingel Demedts. AZ Delta provides clinical operations infrastructure for investigating CIS-DPI in stage IV NSCLC patients.
  • CHU Ambroise ParécoreStrategic or Co-development Partner · 1 February 2023CHU Ambroise Paré (Mons, Belgium) is a clinical trial site for the CIS-DPI-01 Phase I/IIa trial. Principal investigator: Dr. Stephane Holbrechts. The hospital provides oncology clinical trial capabilities for the investigation of inhaled cisplatin in lung cancer patients.
  • Grand Hôpital de Charleroi (GHdC)coreStrategic or Co-development Partner · 1 February 2023Grand Hôpital de Charleroi (Charleroi, Belgium) is a clinical trial site for the CIS-DPI-01 Phase I/IIa trial. Principal investigator: Dr. Benoît Colinet. Located in the same region as the company's headquarters, GHdC provides clinical trial infrastructure for the CIS-DPI investigation.
  • CHU LiègecoreStrategic or Co-development Partner · 1 February 2023CHU Liège (Liège, Belgium) is a clinical trial site for the CIS-DPI-01 Phase I/IIa trial. Principal investigator: Dr. Anne Sibille. CHU Liège provides oncology clinical trial capabilities for the investigation of inhaled cisplatin-based dry powder in combination with standard-of-care immunotherapy in stage IV NSCLC.
  • SMB TechnologycoreStrategic or Co-development Partner · 1 December 2019SMB Technology is a Belgian-based pharmaceutical company specialized in innovative drug formulations, particularly respiratory products based on Dry Powder for Inhalation (DPI) technologies. SMB Technology is represented on InhaTarget's Board of Directors by Mrs. Caroline Baudier (Managing Director), bringing solid expertise in inhalation project development. SMB is part of the SMB group dedicated to R&D and production of innovative pharmaceutical products using advanced drug delivery solutions.
  • University of Brussels (ULB)coreStrategic or Co-development Partner · 1 August 2019InhaTarget Therapeutics is a spin-off company from the University of Brussels (ULB), specifically from the Unit of Pharmaceutics and Biopharmaceutics led by Pr. Karim Amighi and Pr. Nathalie Wauthoz. The technology platform underlying the company's activities is the result of more than 15 years of research at ULB. The company's scientific advisors and co-founders are affiliated with ULB, and the Brussels office is located at ULB Campus de la Plaine.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

InhaTarget Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Vectura Group: Vectura is a UK-based specialty inhaled drug delivery company developing DPI and nebulized formulations for respiratory diseases, comparable to InhaTarget's inhaled chemo and pulmonary delivery platform. Now owned by Philip Morris, it represents the type of strategic acquirer/licensor that InhaTarget's assets could attract.

Direct peers

  • Pulmatrix: Pulmatrix is a US clinical-stage biopharmaceutical company developing inhaled therapies for respiratory diseases using proprietary dry powder and iSPERSE technology. Directly comparable as a small-cap inhaled drug delivery peer with similar business model and platform-based pipeline approach.
  • Savara Inc: Savara is a clinical-stage specialty pharma developing inhaled therapies for rare respiratory diseases (e.g., molgramostim nebulization). Comparable as a small-cap inhaled therapeutic company pursuing hospital-administered and home-administered inhaled biologics/small molecules for serious pulmonary conditions.
  • TFF Pharmaceuticals: TFF Pharmaceuticals applies thin-film freezing technology to enable dry powder inhalation of molecules that are otherwise difficult to deliver to the lungs. Directly comparable as a platform-based inhaled drug delivery company pursuing multiple indications including oncology and infectious disease.
  • Aradigm Corporation: Aradigm developed inhaled liposomal ciprofloxacin (Aeroquin) and other inhaled therapeutics for severe respiratory infections. Comparable as a clinical-stage inhaled specialty pharma focused on serious pulmonary diseases, though it has since wound down commercial operations.
  • Civitas Therapeutics: Civitas Therapeutics developed inhaled levodopa (ARCUS) for Parkinson's disease using a dry powder pulmonary delivery platform. Directly comparable as a small clinical-stage inhaled specialty pharma acquired by Acorda Therapeutics — representative of typical exit pathway for this peer group.

Emerging players

  • Aprea Therapeutics: Aprea is a clinical-stage oncology biotech developing small molecules that reactivate tumor suppressor p53. Comparable as a similarly-sized clinical-stage oncology biotech, though with a different delivery modality (oral/systemic vs. inhaled).
  • Synspira Therapeutics: Synspira develops inhaled glycopolymer-based therapies for cystic fibrosis and other chronic respiratory diseases. Comparable as a niche inhaled therapeutic company focused on serious pulmonary indications with similar formulation technology approach.
  • Novocure: Novocure develops Tumor Treating Fields, an alternative physical modality for solid tumors including NSCLC. Comparable as a later-stage commercial-stage oncology company that built a niche around non-chemo/non-systemic treatment of lung cancer — relevant for understanding the commercial opportunity for non-systemic lung cancer therapies.

Others

  • SMB Technology: Belgian pharmaceutical company specialized in DPI formulation and inhalation product development; InhaTarget's Board partner and effective CDMO. Comparable as a domain peer and key ecosystem enabler for inhaled drug development in the same geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

InhaTarget Therapeutics social profiles

Digital presence

InhaTarget Therapeutics compliance and trust

Trust signal

Compliance1 record

InhaTarget Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InhaTarget Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

InhaTarget Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InhaTarget Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InhaTarget Therapeutics

What does InhaTarget Therapeutics do?

InhaTarget Therapeutics develops innovative inhalation formulations (dry powder for inhalation and nanomedicine-based delivery) to improve treatment of severe respiratory diseases, with a primary focus on lung cancer. The lead asset CIS-DPI is a cisplatin-based dry powder administered 5 times weekly at home in combination with standard-of-care immunotherapy for first-line Stage IV NSCLC patients, currently in Phase I/IIa clinical trials across 5 Belgian hospital sites. The pipeline additionally includes two preclinical inhaled chemotherapy compounds and a first-in-class inhaled STING-pathway immunotherapy nanomedicine.

Is InhaTarget Therapeutics a public or private company?

InhaTarget Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was InhaTarget Therapeutics founded?

InhaTarget Therapeutics was founded in 2019. It employs 1 to 10 people.

Where is InhaTarget Therapeutics based?

InhaTarget Therapeutics is headquartered in Ixelles, Belgium, in the Europe region.

How does InhaTarget Therapeutics make money?

Three revenue lines are on record. Inhaled Chemotherapy Products are the primary driver. The others are inhaled Immunotherapy (STING Pathway Nanomedicine) and non-dilutive Public Funding.

Who are InhaTarget Therapeutics's main competitors?

Vectura Group is listed as a broad incumbent. Direct peers are Pulmatrix, Savara Inc, TFF Pharmaceuticals, Aradigm Corporation and Civitas Therapeutics. Emerging players are Aprea Therapeutics, Synspira Therapeutics and Novocure. SMB Technology is listed as an others.

Does InhaTarget Therapeutics have an API?

No public API is recorded for InhaTarget Therapeutics.

What industry is InhaTarget Therapeutics in?

InhaTarget Therapeutics's product category is Inhaled Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals